Inflammatory & Immunological Biomarkers
The Biomarker Summit 2018, to be held on March 20-21, 2018 in San Diego, CA at the Hilton San Diego Resort & Spa, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.
Topics to be covered:
A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.
Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in four major therapeutic areas, formally organized in the following tracks:
Joint Plenary Sessions:
- Opening Keynote Session – Historical Perspective & Current State of the Industry
- Round Table Discussions – Neuroinflammation, Neuroimaging and Translational Biomarkers
- Lunch Session: Big Data Analytics & Bioinformatics for Biomarkers Development
- Award Ceremony & Closing Keynote Session – Predictions for future
- Immuno-Oncology Biomarkers
- Circulating Tumor Cells, Microvesicles, DNA and RNA
- Biomarkers for Early Identification of Neurological Disease
- Monitoring Progression and Treatment Efficacy using Biomarkers
- Biomarkers for Early Progressive Inflammatory & Immunological Diseases
- Biomarkers as Surrogate Endpoints for Clinical Trials
- Biomarkers for Heart Failure & Acute Coronary Syndrome
- Biomarkers for Metabolic Syndrome & Cardiovascular Risk
We hope to see you there!
The 2018 Advisory Committee
|2018 ADVISORY BOARD MEMBERS|
|Andreas Jeromin, Quanterix|
|Andrew Penn, Victoria General Hospital|
|Bruce W.M.Jordan, Roche Diagnostics|
|Cristina Stefan, Roche|
|Daniel Chelsky, Caprion Biosciences|
|Frédéric Baribaud, Janssen|
|Gary Gustavsen, Health Advances|
|Mark Frasier, Michael J. Fox Foundation|
|Michael Heller, University of California, San Diego|
|Parag Mallick, Stanford University|
|Pierluigi Mauri, Proteomics and Metabolomics Laboratory – CNR, Institute for Biomedical Tecnologies (ITB-CNR)|
|Stephen Pennington, University College Dublin|
The 2018 sponsorship is currently in process.
Please come back and visit this page for updates.
BELOW ARE THE SPONSORS FROM 2017.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Myriad RBM, Inc. is the world's leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.
SomaLogic measure 1,310 proteins simultaneously from 65 µL of sample with high sensitivity, specificity and reproducibility. We enable biomarker discovery, better understanding of pathways, target identification, target validation and understanding of off-target effects. We can scale our technology from a large plex (1,310 proteins), to individual analytes, and to panels.
Sengenics is a immuno-diagnostics and therapeutics biotechnology company. Our core focus is leveraging our core patented Immunome technology for discovering antibody-based therapeutics and diagnostic signatures for immune system disorders. Sengenics owns the set of patents for both the fundamental underlying technology as well as commercialisation and joint IP rights for discoveries and applications made with the Immunome platform.
Zimmer & Peacock is the world leader in electrochemical Biosensor design, development, manufacturing and troubleshooting. We partner with you on all aspects of in vitro POC diagnostic devices and sensors. We specialize in translating biomarkers into point of care devices.
Cofactor is leading the charge on moving RNA-seq out of discovery and into diagnostics. Working with the largest life-science and pharmaceutical companies, we’ve developed streamlined and scalable protocols to interrogate RNA. By standardizing RUO RNA-seq products, and developing validated CAP/CLIA assays, we're trusted partners in advancing precision medicine.
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.